AL-amyloidosis was previously known as “primary systemic amyloidosis”. In AL amyloidosis, the amyloid forming protein is derived from the light chain component of a protein in the blood called monoclonal immunoglobulin. These light chains are produced by abnormal cells (called plasma or B cells) which are usually in the bone marrow. The underlying bone marrow disorder is known by many different names (MGUS – monoclonal gammopathy of undetermined significance, plasma cell dyscrasia, paraprotein disorder etc) and in most cases is very subtle.
A disease-specific Optimal Care Pathway has been developed for AL-amyloidosis, accompanied by a quick reference guide and patient guide, specially designed to help people in Australia with blood cancer, and their loved ones. The OCP patient guides are suitable to be shared with your patients, to ensure they are informed of their upcoming blood cancer journey.
AL-amyloidosis
Comprehensive Optimal Care Pathway for AL-amyloidosis
A comprehensive pathway to encourage consistent optimal treatment and supportive care at each stage of a patient’s journey
Quick reference guide for the OCP for AL-amyloidosis
A quick reference guide to encourage consistent optimal treatment and supportive care at each stage of a patient’s journey
Guide to best cancer care for AL-amyloidosis
A simplified guide that is suitable for sharing with your patient
Optimal Care Pathways are one of the key recommendations in Australia’s National Strategic Action Plan for Blood Cancer. They will help you, as a health professional, provide nationally consistent, high-quality, evidence-based information at each stage of the blood cancer pathway, from diagnosis and treatment to ongoing care.
